ME

MEDINET Co., Ltd.

A CDMO for cell therapy and regenerative medicine development & manufacturing.

2370 | T

Overview

Corporate Details

ISIN(s):
JP3920990003
LEI:
Country:
Japan
Address:
品川区勝島一丁目5番21号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MEDINET Co., Ltd. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the regenerative medicine and cell therapy sectors. Since its establishment in 1999, the company has provided comprehensive, one-stop solutions across the entire value chain, from pre-clinical research and technology transfer to manufacturing and commercial launch. Key services include process development, quality control, quality assurance, and logistics. MEDINET operates an advanced cell processing facility compliant with Japanese, US, and European GCTP standards, leveraging its extensive experience and deep expertise in Japan's regulatory framework to support its clients' development and manufacturing needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 08:09
Registration Form
有価証券届出書(参照方式)
Japanese 173.2 KB
2025-05-14 08:33
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-05-14 08:32
Interim / Quarterly Report
半期報告書-第30期(2024/10/01-2025/09/30)
Japanese 204.7 KB
2024-12-26 04:04
AGM Information
臨時報告書
Japanese 25.2 KB
2024-12-18 07:40
Registration Form
確認書
Japanese 8.3 KB
2024-12-18 07:38
Governance Information
内部統制報告書-第29期(2023/10/01-2024/09/30)
Japanese 21.6 KB
2024-12-18 07:35
Annual Report
有価証券報告書-第29期(2023/10/01-2024/09/30)
Japanese 1.3 MB
2024-05-14 08:02
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-05-14 08:00
Quarterly Report
四半期報告書-第29期第2四半期(2024/01/01-2024/03/31)
Japanese 200.2 KB
2024-02-13 07:04
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-02-13 07:01
Quarterly Report
四半期報告書-第29期第1四半期(2023/10/01-2023/12/31)
Japanese 152.4 KB
2023-12-21 07:03
Registration Form
確認書
Japanese 8.3 KB
2023-12-21 07:02
Governance Information
内部統制報告書-第28期(2022/10/01-2023/09/30)
Japanese 21.7 KB
2023-12-21 07:01
Annual Report
有価証券報告書-第28期(2022/10/01-2023/09/30)
Japanese 1.3 MB
2023-08-10 08:02
Report Publication Announcement
確認書
Japanese 8.3 KB

Automate Your Workflow. Get a real-time feed of all MEDINET Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MEDINET Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MEDINET Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America
SLGL
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany
SAZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.